Overview
Keros Q3 net loss narrows to $7.3 mln from $53 mln, largely due to Takeda license revenue
Company plans to return $375 mln of excess capital to stockholders
Research and development expenses decrease as Takeda assumes elritercept costs
Outlook
Company expects cash to fund operations into first half of 2028
Takeda plans Phase 3 trial for elritercept in myelodysplastic syndromes
Keros advancing Phase 2 trial for KER-065 in Duchenne muscular dystrophy
Result Drivers
TAKEDA LICENSE REVENUE - Revenue from license agreement with Takeda significantly reduced net loss
R&D EXPENSES DECREASE - Transition of elritercept-related R&D expenses to Takeda lowered costs
ADMIN EXPENSES INCREASE - External costs increased general and administrative expenses despite reduced headcount
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Net Income | -$7.28 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 5 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Keros Therapeutics Inc is $22.50, about 30.9% above its November 4 closing price of $15.55
Press Release: ID:nGNX8Gztlt
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)